Cargando…
COVID-19 in Cladribine-treated patient with multiple sclerosis
Case report describing a patient infected with COVID-19 after initiation of Cladribine, with a favorable disease course and positive seroconversion.
Autores principales: | Haham, Nitsan, Vaknin-Dembinsky, Adi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8349393/ https://www.ncbi.nlm.nih.gov/pubmed/34390951 http://dx.doi.org/10.1016/j.jneuroim.2021.577690 |
Ejemplares similares
-
Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis
por: Brill, Livnat, et al.
Publicado: (2022) -
Description of 3 patients with myasthenia gravis and COVID-19
por: Rein, Netaniel, et al.
Publicado: (2020) -
Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine()
por: Brill, Livnat, et al.
Publicado: (2022) -
Cerebrospinal fluid of progressive multiple sclerosis patients reduces differentiation and immune functions of oligodendrocyte progenitor cells
por: Zveik, Omri, et al.
Publicado: (2022) -
Severe Acute Respiratory Syndrome Coronavirus 2 Third Vaccine Immune Response in Multiple Sclerosis Patients Treated with Ocrelizumab
por: Brill, Livnat, et al.
Publicado: (2022)